***Background.*** Tobramycin Inhalation Solution (TIS) for chronic suppressive therapy or eradication of *Pseudomonas aeruginosa*is standard for patients with cystic fibrosis. Increasingly, TIS is used off-label to treat other infectious complications of the respiratory tract. Children in pediatric long term care facilities (pLTCFs) have complex comorbid conditions often including respiratory disorders, e.g., bronchopulmonary dysplasia and chronic lung disease. We sought to describe the use of TIS in pLTCFs.

***Methods.*** From October 2013 to March 2014 we reviewed the medical records of all children residing at 3 pLTCFs in the New York metropolitan area to determine if they had received TIS and if so, the indication for treatment. Statistical analyses were completed with Student\'s t-test or Pearson\'s chi-square.

***Results.*** During the study period, 8% of residents (25/314) were treated with TIS (10, 8, and 7 were at Site 1, 2, and 3, respectively). The most common indication was tracheitis (n = 10, 40%) followed by "secretion management" (n = 5, 20%). Other indications included atelectasis (n = 2), prophylaxis (n = 2), reactive airway disease (n = 1), and tracheal colonization (n = 1). No indication was documented for 4 (16%) residents. Most residents (n = 15) were on TIS courses of monthly on-off cycles and 10 received 1 course (range: 4-21 days). Bacterial cultures of the respiratory tract were obtained for 5 (20%) of 25 residents on TIS and were positive for *Serratia marcescens* (n = 2), *P. aeruginosa* (n = 2), and both *S. marescens and P. aeruginosa*(n = 1). Susceptibility testing was available for 4 isolates and all were susceptible to tobramycin. Residents who received TIS were older and more likely to have a tracheostomy and a chronic respiratory disorder (Table).

###### 

Characteristics of pLTCF residents who did and did not receive TIS

  Characteristics                TIS N=25 (%)   No TIS N=289 (%)   *P*
  ------------------------------ -------------- ------------------ ------------
  Mean age, years                10.6           8.2                **0.05**
  Male                           16 (64)        134 (46)           0.09
  Tracheostomy                   22 (88)        106 (37)           **\<0.01**
  Chronic respiratory disorder   19 (76)        156 (54)           **0.03**

***Conclusion.*** Off-label TIS use was observed in all 3 PLTCFs. Further research should determine the efficacy of TIS use in this population and monitor the emergence of multidrug-resistant bacteria in this unique population.
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